{"organizations": [], "uuid": "044f548f35e937bf215394e6a322c74c30287179", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cymabay-announces-12-week-and-26-w/brief-cymabay-announces-12-week-and-26-week-results-from-phase-2-study-of-seladelpar-in-patients-with-primary-biliary-cholangitis-idUSFWN1RO0N1", "country": "US", "domain_rank": 408, "title": "BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-11T14:50:00.000+03:00", "replies_count": 0, "uuid": "044f548f35e937bf215394e6a322c74c30287179"}, "author": "", "url": "https://www.reuters.com/article/brief-cymabay-announces-12-week-and-26-w/brief-cymabay-announces-12-week-and-26-week-results-from-phase-2-study-of-seladelpar-in-patients-with-primary-biliary-cholangitis-idUSFWN1RO0N1", "ord_in_thread": 0, "title": "BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "cymabay therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News  52 AM / in 10 minutes BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis Reuters Staff 1 Min Read \nApril 11 (Reuters) - CymaBay Therapeutics Inc: \n* WEEK RESULTS FROM ITS ONGOING PHASE 2 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AT THE INTERNATIONAL LIVER CONGRESSâ„¢ 2018 * SELADELPAR APPEARS SAFE AND WELL TOLERATED \n* RESULTS FROM PHASE 2 OF SELADELPAR STUDY REAFFIRM PLANS FOR ADVANCING TO PHASE 3 IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-11T14:50:00.000+03:00", "crawled": "2018-04-11T15:08:05.029+03:00", "highlightTitle": ""}